AI
IOVA icon

Atom Investors’s Iovance Biotherapeutics IOVA Stock Holding History

Atom Investors’s Portfolio IOVA Stock Details IOVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-113,921
Closed -$247K – 694
2025
Q3 		$247K Buy
+113,921
New +$269K 0.02% 473
2021
Q2 		– Sell
-8,172
Closed -$259K – 287
2021
Q1 		$259K Buy
8,172
+541
+7% +$22.4K 0.04% 201
2020
Q4 		$354K Buy
+7,631
New +$303K 0.04% 265
2020
Q1 		– Sell
-78,146
Closed -$2.16M – 353
2019
Q4 		$2.16M Sell
78,146
-14,568
-16% -$331K 0.18% 127
2019
Q3 		$1.69M Sell
92,714
-143,622
-61% -$3.18M 0.12% 162
2019
Q2 		$5.79M Buy
+236,336
New +$3.56M 0.38% 83

Other funds holding IOVA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
MFM
MHR Fund Management New York $1.37B AUM 68.35% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
ICM
Invenomic Capital Management Boston, Massachusetts $2.18B AUM 0.03% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
LFCM
Long Focus Capital Management San Juan, Puerto Rico $3.8B AUM 7.31% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Atom Investors's IOVA Position: Q4 2025 in Review

Atom Investors sold out of Iovance Biotherapeutics (IOVA) in Q4 2025, closing a stake of 113,921 shares — an estimated $247K sold.

Atom Investors first reported a position in IOVA in Q2 2019 and held it in 6 quarters. The position peaked at $5.79M in Q2 2019. 264 funds tracked by Wall St. Rank hold IOVA as of Q4 2025.

  • Atom Investors reported no remaining Iovance Biotherapeutics position as of Q4 2025 after selling out during the quarter.
  • Atom Investors sold 113,921 Iovance Biotherapeutics shares in Q4 2025, an estimated $247K.
  • Atom Investors first reported a position in Iovance Biotherapeutics in Q2 2019 and held it in 6 quarters.
  • Atom Investors's Iovance Biotherapeutics position peaked at $5.79M in Q2 2019.
  • 264 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q4 2025.

Based on Atom Investors's 13F filing for Q4 2025, filed 17 Feb 2026.